Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling. - Wikidata - wikimedia - TriplyDB

Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.

Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.

http://www.wikidata.org/entity/Q35474544

about

Intravital imaging reveals new ancillary mechanisms co-opted by cancer cells to drive tumor progression The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer Impacts of Ionizing Radiation on the Different Compartments of the Tumor Microenvironment β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer Tension in Cancer The complexity of integrins in cancer and new scopes for therapeutic targeting Cellular and molecular regulation of innate inflammatory responses Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.Intravital imaging of mouse urothelium reveals activation of extracellular signal-regulated kinase by stretch-induced intravesical release of ATP Intravital Förster resonance energy transfer imaging reveals osteopontin-mediated polymorphonuclear leukocyte activation by tumor cell emboli.Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases Quantitative Multiscale Cell Imaging in Controlled 3D Microenvironments.Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.Melanoma Cells Block PEDF Production in Fibroblasts to Induce the Tumor-Promoting Phenotype of Cancer-Associated Fibroblasts Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription.Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors.β1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer Characterization of site-specific glycosylation of secreted proteins associated with multi-drug resistance of gastric cancer.Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.VEGF blockade enhances the antitumor effect of BRAFV600E inhibition.β1 integrin- and JNK-dependent tumor growth upon hypofractionated radiation.Tetraspanin 8 is a novel regulator of ILK-driven β1 integrin adhesion and signaling in invasive melanoma cells.Cuprous oxide nanoparticles inhibit prostate cancer by attenuating the stemness of cancer cells via inhibition of the Wnt signaling pathway.Immunogenic, cellular, and angiogenic drivers of tumor dormancy--a melanoma view.Eradicating tumor drug resistance at its YAP-biomechanical roots Crosstalk signaling in targeted melanoma therapy.Preclinical Advances with Multiphoton Microscopy in Live Imaging of Skin Cancers.Unsuccessful mitosis in multicellular tumour spheroids Future Perspective of Single-Molecule FRET Biosensors and Intravital FRET Microscopy.The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.Molecular Pathways: Endothelial Cell FAK-A Target for Cancer Treatment.Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior.YAP/TAZ at the Roots of Cancer.Metastatic melanoma moves on: translational science in the era of personalized medicine.Homeostasis Back and Forth: An Ecoevolutionary Perspective of Cancer.The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas.

P2860

Q26745311-64E4DD1C-3FBA-4DBD-817A-BF30205A7E73 Q26747247-A899DC7C-2A0A-4010-9EB3-3EF2930894B8 Q26750420-C476429B-7252-45C5-94ED-2B62A4B986E7 Q26774789-A906A157-3E66-468E-B7D2-BD2B22611C1A Q28066437-CDB4F904-EAAD-4C21-86CD-65B8B5CADD19 Q28073343-4A866EE4-C8AB-4CFA-8A8E-3576C60342F5 Q28079497-219DEA0D-12D5-4CB0-B167-6C77110B73AA Q30251581-28CB924C-6848-4684-9489-C76B4F9DB01C Q33769541-440A20FE-99EE-4F08-8255-1D4344580238 Q35868895-79D7F39C-D6D7-4DE2-8CD9-8A4AE63D709B Q36208849-9A8894AC-49E1-43C3-9859-9691ED5642D3 Q36222369-F4CCF146-4C07-46B8-83A2-253D7AA2E8AA Q36533041-4FBA05EA-7E73-422E-B4B1-EF72ECF6A693 Q36667823-6AFBA872-82D0-41C0-91B0-1C14FB0C0096 Q36774894-C8E7D4B6-E048-4438-9F06-EAB00F541462 Q36918170-C8D0F197-0B1E-4A12-9A7E-FAF84993C56D Q36989342-22DF5C02-CB15-4A5A-8B74-0B2C72716C2E Q37157064-8550FF91-A82C-4553-8BEE-38C608709825 Q37190236-F321C38F-40E4-4925-BB48-D10443C75709 Q37286353-82E3E7D6-3C39-4861-BF0D-42BCD581F29A Q37295326-4B0C8200-FD8E-4DE5-8A01-C4B38EDEEA58 Q37595877-6424883A-3335-4FB5-8616-1E1540B22C88 Q37618011-84433623-F1B2-409E-93E9-465D156DA9D0 Q37619636-C61A691C-C802-4D95-9591-82E33E1DE453 Q37725588-983A0D5D-34DD-4D3E-A0A6-F1F7ABCCF764 Q37739979-5ED7AF34-09DF-43C2-8A8D-47D68D72ED77 Q38619615-8CC82118-0223-41F4-ABAE-7CB8E56DD786 Q38697752-10D30C8D-00E9-461D-AE19-D9445A0E764C Q38757522-7DAA9764-EF1C-49D4-8156-E143D803F1E2 Q38795140-D0B1B80C-7331-472E-80A7-CEB95D94D2EC Q38826784-F9DDF8C6-9E9C-4C6F-9BE3-D6E883C9BC7A Q38836055-E801B00F-4E87-495A-A5D2-0EAA2148814C Q38843111-21ECB6A9-AF77-4D36-BA5C-60490281FBA5 Q38843575-C9EC7669-0C7E-4D53-832E-346038767A6B Q38854580-C7175AFB-4098-4C9C-AB0E-33CF15CE3B96 Q38856246-F3E29390-9F6E-43E8-917B-28EF82731DF7 Q38864941-9FB00FEC-2AB7-41C8-B603-2DA4ADA56281 Q38891959-DF3B6AB9-C144-4079-A2BE-560A303EFA76 Q38910371-8395329C-B18F-4639-A05B-63A4156AA9DA Q38922999-E9509D44-7593-4911-B301-00BF47507C46

P2860

Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.

http://www.wikidata.org/entity/Q35474544

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Intravital imaging reveals how ...... igh integrin β1/FAK signaling.

@ast

Intravital imaging reveals how ...... igh integrin β1/FAK signaling.

@en

type

label

Intravital imaging reveals how ...... igh integrin β1/FAK signaling.

@ast

Intravital imaging reveals how ...... igh integrin β1/FAK signaling.

@en

prefLabel

Intravital imaging reveals how ...... igh integrin β1/FAK signaling.

@ast

Intravital imaging reveals how ...... igh integrin β1/FAK signaling.

@en

P1433

Q35474544-E1CE3EA8-C1E4-4213-8B7B-F84760A3A79C

P1476

Q35474544-87693587-567C-47CB-BAE6-0BF60AD20FEB

P2093

Q35474544-0A1A9D2E-6076-4079-A100-C4C6736BFA35

Q35474544-29A425A8-72B2-4DF4-86A7-0A19E9DC0A20

Q35474544-37A8B593-1B88-46B7-82C3-B8B72BD66BA0

Q35474544-58134FEC-D0FC-4C3C-A80E-CAB3B85148C5

Q35474544-93341BB6-320E-4614-9A15-B4C5B4FF6D47

Q35474544-C7366E1C-2C48-414E-B2C4-CD0511D3432D

Q35474544-D5300C3A-2544-491A-BD50-79D13A4A1ED9

P2860

Q35474544-01B7B2FF-918A-41E9-BCE7-3E3B6A34BFF3

Q35474544-06FC2037-33FC-4A60-ABE8-5020307768EF

Q35474544-0E78FEF2-A7EF-4308-AAD5-98BCA7699B92

Q35474544-16025692-59DE-4AB8-B000-614A2257B44D

Q35474544-1DFECDF5-697E-4DAF-938C-AA6217A1BF60

Q35474544-2D4EB010-B0DC-4B23-A3BF-CA61DFC49658

Q35474544-37B01700-31B9-4BFC-A030-55AE4496A3D9

Q35474544-3F81C50D-5F9F-4D49-A0DE-D43661D3BDF1

Q35474544-43EE43B5-988C-47A4-8025-42814DDF5F13

Q35474544-446523D8-6B8F-4CF0-948B-F41DE75EC0BE

P304

Q35474544-DEFE5C6D-25CA-44FB-A44D-1170442281E8

P31

Q35474544-75BBBD99-4F04-476E-955A-FB202C43A81C

P356

Q35474544-EC06F123-1687-4B00-88E8-E905E01A23FA

P433

Q35474544-23355679-786B-4018-93DD-D3CA3613AE3C

P478

Q35474544-019BBF17-826F-4914-984E-1403F77E2E3A

P50

Q35474544-A20BDDE6-EC0F-4B46-A148-4F932A06B01E

Q35474544-F21C77D6-FB7A-4036-BCEB-D9266EF41217

P577

Q35474544-A24F153D-6ABE-4902-B545-92B34AE1F056

P5875

Q35474544-F538E0CF-2D1D-4001-9AE4-DA9FEB8A1913

P698

Q35474544-3610D38B-EAB8-4836-B255-1EFF9008DDA1

P932

Q35474544-6B9B17DF-063F-45EB-BB85-204382F00DCE

P356

J.CCELL.2015.03.008

P1433

P1476

Intravital imaging reveals how ...... igh integrin β1/FAK signaling.

@en

P2093

Amaya Viros

http://www.w3.org/2001/XMLSchema#string

Bradley Spencer-Dene

http://www.w3.org/2001/XMLSchema#string

Eishu Hirata

http://www.w3.org/2001/XMLSchema#string

James Larkin

http://www.w3.org/2001/XMLSchema#string

Maria Romina Girotti

http://www.w3.org/2001/XMLSchema#string

Richard Marais

http://www.w3.org/2001/XMLSchema#string

Steven Hooper

http://www.w3.org/2001/XMLSchema#string

P2860

B-Raf and the inhibitors: from bench to bedside

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options

FAK in cancer: mechanistic findings and clinical applications

Intravital FRET imaging of tumor cell viability and mitosis during chemotherapy

P304

574-588

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCELL.2015.03.008

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Michiyuki Matsuda

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275047555

http://www.w3.org/2001/XMLSchema#string

P698

25873177

http://www.w3.org/2001/XMLSchema#string

P932

4402404

http://www.w3.org/2001/XMLSchema#string